LaNova Medicines Limited clinical trials

Acquired by Sino Biopharmaceutical Limited

The registry lists 18 studies whose lead sponsor is LaNova Medicines Limited. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 18 of 18. All Sino Biopharmaceutical Limited studies →

• A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid TumorsNot yet recruitingNCT07847905Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingNCT06682780Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid TumorsRecruitingNCT07669415Phase 2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid TumorsNot yet recruitingNCT07694765Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction AdenocarcinomaRecruitingNCT07362186Phase 3

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• Phase II Study of LM-24C5RecruitingNCT07387081Phase 2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Study of LM-350 in Subjects With Advanced Solid TumoursRecruitingNCT07112222Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid TumoursRecruitingNCT06868199Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Study of LM-24C5 For Advanced Solid TumorsRecruitingNCT06187402Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• Study of LM-299 in Subjects Advanced Malignant TumorsRecruitingNCT06650566Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid TumoursNot yet recruitingNCT06873854Phase 2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant TumorsRecruitingNCT05615974Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsActive, not recruitingNCT05518045Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell DiseasesWithdrawnNCT05647512Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid TumoursTerminatedNCT05255484Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• Study of LM-061 in Subjects in Advanced TumorsTerminatedNCT04737122Phase 1

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced TumoursTerminatedNCT04882176Phase 1/2

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group

• Study of LM-102 in Subjects in Advanced TumorsTerminatedNCT04735796Phase 1

  Sponsor listed in the registry: LaNova Medicines Limited · LaNova Medicines Limited — acquired company within the Sino Biopharmaceutical Limited group